X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB VENUS REMEDIES UNICHEM LAB/
VENUS REMEDIES
 
P/E (TTM) x 282.0 -1.5 - View Chart
P/BV x 0.6 0.1 604.3% View Chart
Dividend Yield % 2.6 0.0 -  

Financials

 UNICHEM LAB   VENUS REMEDIES
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
VENUS REMEDIES
Mar-18
UNICHEM LAB/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs382126 303.4%   
Low Rs23461 383.1%   
Sales per share (Unadj.) Rs116.3301.8 38.5%  
Earnings per share (Unadj.) Rs-18.9-24.9 76.1%  
Cash flow per share (Unadj.) Rs-11.72.5 -461.4%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %1.60-  
Book value per share (Unadj.) Rs381.0293.3 129.9%  
Shares outstanding (eoy) m70.3412.34 570.0%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.60.3 855.0%   
Avg P/E ratio x-16.3-3.8 433.1%  
P/CF ratio (eoy) x-26.236.7 -71.4%  
Price / Book Value ratio x0.80.3 253.6%  
Dividend payout %-26.40-   
Avg Mkt Cap Rs m21,6681,154 1,878.0%   
No. of employees `0002.30.9 246.5%   
Total wages/salary Rs m2,006393 510.4%   
Avg. sales/employee Rs Th3,587.84,026.1 89.1%   
Avg. wages/employee Rs Th880.0425.0 207.1%   
Avg. net profit/employee Rs Th-583.7-331.8 175.9%   
INCOME DATA
Net Sales Rs m8,1803,724 219.7%  
Other income Rs m61023 2,711.6%   
Total revenues Rs m8,7903,747 234.6%   
Gross profit Rs m-1,320395 -334.4%  
Depreciation Rs m505338 149.3%   
Interest Rs m80354 22.6%   
Profit before tax Rs m-1,295-275 470.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3332 105.8%   
Profit after tax Rs m-1,331-307 433.7%  
Gross profit margin %-16.110.6 -152.2%  
Effective tax rate %-2.6-11.5 22.5%   
Net profit margin %-16.3-8.2 197.4%  
BALANCE SHEET DATA
Current assets Rs m23,3182,638 884.0%   
Current liabilities Rs m4,6352,305 201.1%   
Net working cap to sales %228.48.9 2,554.0%  
Current ratio x5.01.1 439.5%  
Inventory Days Days122135 89.9%  
Debtors Days Days12146 262.2%  
Net fixed assets Rs m8,1634,871 167.6%   
Share capital Rs m141123 114.0%   
"Free" reserves Rs m26,6603,496 762.7%   
Net worth Rs m26,8013,619 740.5%   
Long term debt Rs m31,374 0.2%   
Total assets Rs m31,8907,509 424.7%  
Interest coverage x-15.20.2 -6,803.9%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.30.5 51.7%   
Return on assets %-3.90.6 -621.3%  
Return on equity %-5.0-8.5 58.6%  
Return on capital %-4.51.6 -287.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m4,3560-   
Fx outflow Rs m0517 0.0%   
Net fx Rs m4,356-517 -843.4%   
CASH FLOW
From Operations Rs m-1,123514 -218.4%  
From Investments Rs m16,487-123 -13,392.9%  
From Financial Activity Rs m-8,811-387 2,276.2%  
Net Cashflow Rs m6,5524 156,000.0%  

Share Holding

Indian Promoters % 50.1 32.9 152.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 0.2 8,388.9%  
FIIs % 3.0 0.6 517.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 66.4 47.7%  
Shareholders   20,176 20,121 100.3%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   GLENMARK PHARMA  FULFORD INDIA  WYETH LTD  DIVIS LABORATORIES  ALEMBIC LTD  

Compare UNICHEM LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and IT Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector and IT sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

This is Why You Need to Buy Small Cap Stocks Now(The 5 Minute Wrapup)

Mar 15, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Mar 20, 2019 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS